Megan Griffiths

Dr. Megan Griffiths

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2020 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
CSCatherine E. Simpson
Catherine E. Simpson
JCJenny Y. Chen
Jenny Y. Chen
RDRachel L. Damico
Rachel L. Damico
PHPaul M. Hassoun
Paul M. Hassoun
LMLisa J. Martin
Lisa J. Martin
AEAllen D. Everett
Allen D. Everett
The pro-inflammatory cytokine interleukin (IL)-6 has been associated with outcomes in small pulmonary arterial hypertension (PAH) cohorts composed largely of patients with severe idiopathic PAH (IPAH). It is unclear whether IL-6 is a marker of critical illness or a mechanistic biomarker of pulmonary vascular remodelling. We hypothesised that IL-6 is produced by pulmonary vascular cells and sought to explore IL-6 associations with phenotypes and outcomes across diverse subtypes in a large PAH cohort.IL-6 protein and gene expression levels were measured in cultured pulmonary artery smooth muscle cells (PASMCs) and endothelial cells (PAECs) from PAH patients and healthy controls. Serum IL-6 was measured in 2017 well-characterised PAH subjects representing each PAH subgroup. Relationships between IL-6 levels, clinical variables, and mortality were analysed using regression models.Significantly higher IL-6 protein and gene expression levels were produced by PASMCs than by PAECs in PAH (p<0.001), while there was no difference in IL-6 between cell types in controls. Serum IL-6 was highest in PAH related to portal hypertension and connective tissue diseases (CTD-PAH). In multivariable modelling, serum IL-6 was associated with survival in the overall cohort (hazard ratio 1.22, 95% CI 1.08–1.38; p<0.01) and in IPAH, but not in CTD-PAH. IL-6 remained associated with survival in low-risk subgroups of subjects with mild disease.IL-6 is released from PASMCs, and circulating IL-6 is associated with specific clinical phenotypes and outcomes in various PAH subgroups, including subjects with less severe disease. IL-6 is a mechanistic biomarker, and thus a potential therapeutic target, in certain PAH subgroups.

1 August 2020 in The Journal of Pediatrics
Verified
Journal Article
Closed access
JCJenny Y. Chen
Jenny Y. Chen
Megan GriffithsMegan Griffiths
Megan Griffiths
JYJun Yang
Jun Yang
MNMelanie K. Nies
Melanie K. Nies
RDRachel L. Damico
Rachel L. Damico
AEAllen D. Everett
Allen D. Everett

1 October 2019 in The Journal of Pediatrics
Verified
Journal Article
Closed access
BDBrooke T. Davey
Brooke T. Davey
RERobert W. Elder
Robert W. Elder
MCMichelle M. Cloutier
Michelle M. Cloutier
NBNicholas Bennett
Nicholas Bennett
JLJi Hyun Lee
Ji Hyun Lee
OTOlga H. Toro-Salazar
Olga H. Toro-Salazar

1 May 2020 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
AEAllen D. Everett
Allen D. Everett
JBJessie P. Buckley
Jessie P. Buckley
GEGreg Ellis
Greg Ellis
JYJun Yang
Jun Yang
DGDavid Graham
David Graham
EGEric M. Graham
Eric M. Graham
Neurodevelopmental delays and disabilities are the most frequent and significant consequences of congenital heart disease (CHD) and its treatment.1 Improvements in surgical techniques and medical support have reduced mortality and morbidity rates, including overt neurological injury (eg, seizure, coma, death) from 50% to 2.3%.2,3 However, sensitive magnetic resonance imaging studies have identified clinically silent, new brain injuries as small focal white matter lesions or strokes in more than 60% of newborns who undergo surgical treatment.4,5 Consistent with the focal nature of these injuries, cognitive deficits at school age are mild, with mean IQs reported in the low end of the reference range.6 However, children with CHD exhibit deficits in multiple neurodevelopmental domains, including speech and language, attention, memory, executive function, visual-spatial skills, and gross and fine motor function, suggesting a more global injury not resolved by magnetic resonance imaging. This high prevalence of low-severity anomalies has been termed the neurodevelopmental signature of CHD.7 Long-term consequences include prevalent behavioral problems and the need for remedial academic services.8 However, a meta-analysis of major surgical intervention trials to improve neurodevelopmental outcomes found that none were successful. Therefore, actionable perioperative factors are lacking to improve neurodevelopmental outcomes in neonates with CHD.9,10

19 October 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
CDCaroline M. Daly
Caroline M. Daly
Megan GriffithsMegan Griffiths
Megan Griffiths
CSCatherine E. Simpson
Catherine E. Simpson
JYJun Yang
Jun Yang
RDRachel L. Damico
Rachel L. Damico
AEAllen D. Everett
Allen D. Everett
Background: Endostatin, an angiogenic inhibitor, is associated with worse pulmonary arterial hypertension (PAH) outcomes in adults and poor lung growth in children. This study sought to assess whether endostatin is associated with disease severity and outcomes in pediatric PAH. Methods and Results: Serum endostatin was measured in cross‐sectional (N=160) and longitudinal cohorts (N=64) of pediatric subjects with PAH, healthy pediatric controls and pediatric controls with congenital heart disease (CHD) (N=54, N=15), and adults with CHD associated PAH (APAH‐CHD, N=185). Outcomes, assessed by regression and Kaplan‐Meier analysis, included hemodynamics, change in endostatin over time, and transplant‐free survival. Endostatin secretion was evaluated in pulmonary artery endothelial and smooth muscle cells. Endostatin was higher in those with PAH compared with healthy controls and controls with CHD and was highest in those with APAH‐CHD. In APAH‐CHD, endostatin was associated with a shorter 6‐minute walk distance and increased mean right atrial pressure. Over time, endostatin was associated with higher pulmonary artery pressure and pulmonary vascular resistance index, right ventricular dilation, and dysfunction. Endostatin decreased with improved hemodynamics over time. Endostatin was associated with worse transplant‐free survival. Addition of endostatin to an NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) based survival analysis improved risk stratification, reclassifying subjects with adverse outcomes. Endostatin was secreted primarily by pulmonary artery endothelial cells. Conclusions: Endostatin is associated with disease severity, disease improvement, and worse survival in APAH‐CHD. Endostatin with NT‐proBNP improves risk stratification, better predicting adverse outcomes. The association of elevated endostatin with shunt lesions suggests that endostatin could be driven by both pulmonary artery flow and pressure. Endostatin could be studied as a noninvasive prognostic marker, particularly in APAH‐CHD.

4 May 2020 in Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
Megan GriffithsMegan Griffiths
Megan Griffiths
JYJun Yang
Jun Yang
AEAllen D. Everett
Allen D. Everett
JMJacky Jennings PhD MPH
Jacky Jennings PhD MPH
GFGrace Freire
Grace Freire
JCJoseph M. Collaco
Joseph M. Collaco